Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Clinical trial NCT01377012 · COMPLETED
Trial details
- NCT number
- NCT01377012
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-08-30
- Primary completion
- 2015-09-09
- Enrollment
- 637
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.